A High Level of Circulating Valine Is a Biomarker for Type 2 Diabetes and Associated with the Hypoglycemic Effect of Sitagliptin.
Xiaoyu LiaoBingyao LiuHua QuLinLin ZhangYongling LuYong XuZhao-Hui LuHongting ZhengPublished in: Mediators of inflammation (2019)
Our findings demonstrate an important effect of Sit on the BCAA valine in T2D patients and HFD-fed mice, revealing a new hypoglycemic mechanism of it. Furthermore, the results suggest that the circulating valine level might be a novel biomarker for T2D and restoring the level of valine might be a potential strategy for diabetes therapy.
Keyphrases
- type diabetes
- end stage renal disease
- cardiovascular disease
- ejection fraction
- glycemic control
- newly diagnosed
- chronic kidney disease
- high fat diet
- prognostic factors
- insulin resistance
- metabolic syndrome
- patient reported outcomes
- mesenchymal stem cells
- risk assessment
- human health
- weight loss
- patient reported
- replacement therapy